This is a problem given the potential for inconsistencies in the receptor status of primary and metastatic tumors, as evidenced by the fact that roughly 20% of metastases in patients with HER2-negative primary tumors are HER2-positive (Priedigkeit et al. 2017). The gene discussed is ERBB2; the disease is metastatic neoplasm.